Published in Lancet on July 19, 2008
Salsalate in Patients Mild to Moderate Alzheimer's Disease (SAL-AD) | NCT03277573
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol (2010) 19.42
Microglia in neurodegenerative disease. Nat Rev Neurol (2010) 5.83
Alzheimer's disease: the challenge of the second century. Sci Transl Med (2011) 4.88
The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov (2011) 4.24
The Alzheimer's disease neuroimaging initiative: progress report and future plans. Alzheimers Dement (2010) 3.85
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Alzheimer's disease: strategies for disease modification. Nat Rev Drug Discov (2010) 3.48
Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci U S A (2011) 3.11
Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. Neuron (2008) 3.08
Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol (2009) 2.87
Resolving controversies on the path to Alzheimer's therapeutics. Nat Med (2011) 2.78
Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc Natl Acad Sci U S A (2013) 2.71
Microglia and brain macrophages in the molecular age: from origin to neuropsychiatric disease. Nat Rev Neurosci (2014) 2.59
Amyloid precursor protein processing and Alzheimer's disease. Annu Rev Neurosci (2011) 2.47
Traumatic brain injury and amyloid-β pathology: a link to Alzheimer's disease? Nat Rev Neurosci (2010) 2.34
Beneficial effect of human anti-amyloid-beta active immunization on neurite morphology and tau pathology. Brain (2010) 2.33
Mechanisms of tau-induced neurodegeneration. Acta Neuropathol (2009) 2.27
Can Alzheimer disease be prevented by amyloid-beta immunotherapy? Nat Rev Neurol (2010) 2.20
Alzheimer's disease as homeostatic responses to age-related myelin breakdown. Neurobiol Aging (2009) 2.14
Changing perspectives regarding late-life dementia. Nat Rev Neurol (2009) 2.04
A review: inflammatory process in Alzheimer's disease, role of cytokines. ScientificWorldJournal (2012) 2.03
Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci (2010) 1.97
Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain (2013) 1.91
Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci (2011) 1.86
The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med (2010) 1.86
A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease. Ann Neurol (2014) 1.83
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem (2011) 1.82
Intraneuronal beta-amyloid accumulation and synapse pathology in Alzheimer's disease. Acta Neuropathol (2010) 1.80
Brain atrophy in healthy aging is related to CSF levels of Aβ1-42. Cereb Cortex (2010) 1.79
Reassessing the amyloid cascade hypothesis of Alzheimer's disease. Int J Biochem Cell Biol (2008) 1.78
Report of the task force on designing clinical trials in early (predementia) AD. Neurology (2010) 1.75
Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014. J Intern Med (2014) 1.75
Loss of tau elicits axonal degeneration in a mouse model of Alzheimer's disease. Neuroscience (2010) 1.70
Serotonin signaling is associated with lower amyloid-β levels and plaques in transgenic mice and humans. Proc Natl Acad Sci U S A (2011) 1.67
Amyloid imaging in aging and dementia: testing the amyloid hypothesis in vivo. Behav Neurol (2009) 1.67
Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci (2010) 1.66
Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease. J Neuropathol Exp Neurol (2009) 1.66
Antibody-aided clearance of extracellular α-synuclein prevents cell-to-cell aggregate transmission. J Neurosci (2012) 1.63
New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br J Clin Pharmacol (2012) 1.62
Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies. Acta Neuropathol (2011) 1.62
Biomarkers in Alzheimer's disease drug development. Nat Med (2010) 1.61
Three dimensions of the amyloid hypothesis: time, space and 'wingmen'. Nat Neurosci (2015) 1.60
The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis (2010) 1.60
Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. Neuroimage (2010) 1.59
The intersection of amyloid beta and tau at synapses in Alzheimer's disease. Neuron (2014) 1.59
Cerebral amyloid angiopathy in the aetiology and immunotherapy of Alzheimer disease. Alzheimers Res Ther (2009) 1.57
Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci U S A (2009) 1.57
Unbiased comparison of sample size estimates from longitudinal structural measures in ADNI. Hum Brain Mapp (2011) 1.53
Amyloid-β--associated clinical decline occurs only in the presence of elevated P-tau. Arch Neurol (2012) 1.48
Amyloid-β associated volume loss occurs only in the presence of phospho-tau. Ann Neurol (2011) 1.44
Immunotherapy for Alzheimer's disease. J Intern Med (2011) 1.43
Desensitization of nicotinic acetylcholine receptors as a strategy for drug development. J Pharmacol Exp Ther (2008) 1.43
Drug repositioning for Alzheimer's disease. Nat Rev Drug Discov (2012) 1.42
Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C]Pittsburgh compound B data. Ann Neurol (2011) 1.40
Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease. Proc Natl Acad Sci U S A (2009) 1.39
Is AD a homogeneous nosologic entity? Yes. J Neural Transm (Vienna) (2013) 1.39
Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol (2008) 1.38
Treatment strategies targeting amyloid β-protein. Cold Spring Harb Perspect Med (2012) 1.37
Biomarkers of Alzheimer's disease. Neurobiol Dis (2008) 1.37
APOE-4 genotype and neurophysiological vulnerability to Alzheimer's and cognitive aging. Annu Rev Clin Psychol (2009) 1.37
Alzheimer's disease therapeutic research: the path forward. Alzheimers Res Ther (2009) 1.37
The Alzheimer's disease mitochondrial cascade hypothesis: an update. Exp Neurol (2009) 1.36
Immunotherapy for Alzheimer's disease: hoops and hurdles. Mol Neurodegener (2013) 1.35
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. Radiology (2012) 1.34
The Alzheimer's disease mitochondrial cascade hypothesis: progress and perspectives. Biochim Biophys Acta (2013) 1.34
Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis (2010) 1.33
Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci (2013) 1.32
Inflammaging as a prodrome to Alzheimer's disease. J Neuroinflammation (2008) 1.29
Recent advances in our understanding of neurodegeneration. J Neural Transm (Vienna) (2009) 1.27
Tau-focused immunotherapy for Alzheimer's disease and related tauopathies. Curr Alzheimer Res (2009) 1.26
The mitochondria-targeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. J Neurosci (2011) 1.26
Initiation and propagation of neurodegeneration. Nat Med (2010) 1.25
The classification of microglial activation phenotypes on neurodegeneration and regeneration in Alzheimer's disease brain. Arch Immunol Ther Exp (Warsz) (2012) 1.23
Will anti-amyloid therapies work for Alzheimer's disease? Lancet (2008) 1.23
Macrophages in Alzheimer's disease: the blood-borne identity. J Neural Transm (Vienna) (2010) 1.22
Cerebrospinal fluid Aβ and tau level fluctuation in an older clinical cohort. Arch Neurol (2012) 1.20
Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets (2009) 1.20
Mild cognitive impairment: pathology and mechanisms. Acta Neuropathol (2011) 1.20
Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease. J Biol Chem (2010) 1.20
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res Ther (2010) 1.20
Amyloid deposits: protection against toxic protein species? Cell Cycle (2009) 1.18
Targeting Abeta and tau in Alzheimer's disease, an early interim report. Exp Neurol (2009) 1.18
Autopsy consent, brain collection, and standardized neuropathologic assessment of ADNI participants: the essential role of the neuropathology core. Alzheimers Dement (2010) 1.18
Why pleiotropic interventions are needed for Alzheimer's disease. Mol Neurobiol (2010) 1.18
Clinical and multimodal biomarker correlates of ADNI neuropathological findings. Acta Neuropathol Commun (2013) 1.15
Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci Res (2011) 1.15
Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta (2010) 1.14
Basic mechanisms of neurodegeneration: a critical update. J Cell Mol Med (2010) 1.13
DNA prime-protein boost increased the titer, avidity and persistence of anti-Abeta antibodies in wild-type mice. Gene Ther (2009) 1.13
Amyloid precursor protein transgenic mouse models and Alzheimer's disease: understanding the paradigms, limitations, and contributions. Alzheimers Dement (2009) 1.13
Immunotherapeutic approaches for Alzheimer's disease. Neuron (2015) 1.13
Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets? Neuromolecular Med (2010) 1.12
Bapineuzumab. Expert Opin Biol Ther (2010) 1.12
Effects of synaptic modulation on beta-amyloid, synaptophysin, and memory performance in Alzheimer's disease transgenic mice. J Neurosci (2010) 1.10
Immunity and inflammation in neurodegenerative diseases. Am J Neurodegener Dis (2013) 1.08
Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease. Neuropsychopharmacology (2013) 1.08
Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets? Immun Ageing (2013) 1.08
Blockade of gap junction hemichannel suppresses disease progression in mouse models of amyotrophic lateral sclerosis and Alzheimer's disease. PLoS One (2011) 1.08
Drug development for Alzheimer's disease: where are we now and where are we headed? Am J Geriatr Pharmacother (2009) 1.07
Therapeutic strategies for tau mediated neurodegeneration. J Neurol Neurosurg Psychiatry (2012) 1.07
Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15
Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83
Microglia in neurodegenerative disease. Nat Rev Neurol (2010) 5.83
Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet (2002) 5.05
11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol (2010) 5.03
Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med (2007) 4.11
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Spectrum of heart disease and risk factors in a black urban population in South Africa (the Heart of Soweto Study): a cohort study. Lancet (2008) 3.11
An outbreak in an intensive care unit of a strain of methicillin-resistant Staphylococcus aureus sequence type 239 associated with an increased rate of vascular access device-related bacteremia. Clin Infect Dis (2007) 2.64
Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57
Statins for the prevention of dementia. Cochrane Database Syst Rev (2009) 2.38
Predominance of heart failure in the Heart of Soweto Study cohort: emerging challenges for urban African communities. Circulation (2008) 2.27
Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol (2008) 2.26
Abeta species removal after abeta42 immunization. J Neuropathol Exp Neurol (2006) 2.25
Prevalence of asthma and asthma action plans in South Australia: population surveys from 1990 to 2001. Med J Aust (2003) 2.23
Development of the European Organisation for Research and Treatment of Cancer quality of life questionnaire module for older people with cancer: The EORTC QLQ-ELD15. Eur J Cancer (2010) 2.20
Trichomonas vaginalis is associated with pelvic inflammatory disease in women infected with human immunodeficiency virus. Clin Infect Dis (2002) 2.14
Coherent concepts are computed in the anterior temporal lobes. Proc Natl Acad Sci U S A (2010) 2.06
Rural doctors and rural backgrounds: how strong is the evidence? A systematic review. Aust J Rural Health (2003) 1.95
Hip fracture risk and subsequent mortality among Alzheimer's disease patients in the United Kingdom, 1988-2007. Age Ageing (2010) 1.93
Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. Lancet (2012) 1.88
Abeta-related angiitis: primary angiitis of the central nervous system associated with cerebral amyloid angiopathy. Brain (2005) 1.87
A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease. Drugs Aging (2003) 1.87
Assessment for selection for the health care professions and specialty training: consensus statement and recommendations from the Ottawa 2010 Conference. Med Teach (2011) 1.86
Microvasculature changes and cerebral amyloid angiopathy in Alzheimer's disease and their potential impact on therapy. Acta Neuropathol (2009) 1.74
C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proc Natl Acad Sci U S A (2012) 1.73
Inequitable provision of optimal services for patients with chronic heart failure: a national geo-mapping study. Med J Aust (2007) 1.67
Skin cancer surgery in Australia 2001-2005: the changing role of the general practitioner. Med J Aust (2007) 1.66
Safety and efficacy of galantamine (Reminyl) in severe Alzheimer's disease (the SERAD study): a randomised, placebo-controlled, double-blind trial. Lancet Neurol (2008) 1.63
Reduction of health status 7 years after addition of chemotherapy to craniospinal irradiation for medulloblastoma: a follow-up study in PNET 3 trial survivors on behalf of the CCLG (formerly UKCCSG). J Clin Oncol (2007) 1.60
Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst Rev (2009) 1.56
Dealing with "rogue" medical students: we need a nationally consistent approach based on "case law". Med J Aust (2008) 1.52
Coping with increasing numbers of medical students in rural clinical schools: options and opportunities. Med J Aust (2008) 1.49
Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med (2005) 1.49
Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage. Lancet Neurol (2004) 1.47
Prediction of the rate of decline in cognitive function in Alzheimer's disease: a model based on simple demographic data and widely used rating scales. Dement Geriatr Cogn Disord (2003) 1.44
Statins for the prevention of dementia. Cochrane Database Syst Rev (2016) 1.43
Mannose receptor expression specifically reveals perivascular macrophages in normal, injured, and diseased mouse brain. Glia (2005) 1.42
Aβ-degrading enzymes: potential for treatment of Alzheimer disease. J Neuropathol Exp Neurol (2011) 1.42
Community participation in organising rural general practice: is it sustainable? Aust J Rural Health (2006) 1.38
Can we afford not to have integrated dementia services? Age Ageing (2007) 1.38
Comprehension of concrete and abstract words in semantic dementia. Neuropsychology (2009) 1.38
Neuropsychiatric syndromes in dementia. Results from the European Alzheimer Disease Consortium: part I. Dement Geriatr Cogn Disord (2007) 1.38
Association between HIV-1 infection, the etiology of genital ulcer disease, and response to syndromic management. Sex Transm Dis (2003) 1.36
Memantine in moderate to severe Alzheimer's disease: a meta-analysis of randomised clinical trials. Dement Geriatr Cogn Disord (2007) 1.35
Factors associated with rural practice among Australian-trained general practitioners. Med J Aust (2003) 1.35
The relationship between resilience and personality traits in doctors: implications for enhancing well being. PeerJ (2013) 1.35
Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). Brain (2005) 1.33
Atypical inflammation in the central nervous system in prion disease. Curr Opin Neurol (2002) 1.32
Decreased expression and activity of neprilysin in Alzheimer disease are associated with cerebral amyloid angiopathy. J Neuropathol Exp Neurol (2006) 1.31
Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis. Acta Neuropathol (2010) 1.31
The multiple roles of the innate immune system in the regulation of apoptosis and inflammation in the brain. J Neuropathol Exp Neurol (2009) 1.30
A time bomb of cardiovascular risk factors in South Africa: results from the Heart of Soweto Study "Heart Awareness Days". Int J Cardiol (2008) 1.29
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology. J Psychopharmacol (2006) 1.29
The membrane attack complex of complement causes severe demyelination associated with acute axonal injury. J Immunol (2002) 1.28
Laboratory productivity and the rate of manual peripheral blood smear review: a College of American Pathologists Q-Probes study of 95,141 complete blood count determinations performed in 263 institutions. Arch Pathol Lab Med (2006) 1.28
Mapping the emergence of heart disease in a black, urban population in Africa: the Heart of Soweto Study. Int J Cardiol (2006) 1.28
Angiotensins in Alzheimer's disease - friend or foe? Trends Neurosci (2009) 1.25
Efficacy of a medical food in mild Alzheimer's disease: A randomized, controlled trial. Alzheimers Dement (2010) 1.24
Statins for the treatment of dementia. Cochrane Database Syst Rev (2010) 1.23
Dermatoscopy in routine practice - 'chaos and clues'. Aust Fam Physician (2012) 1.23
Disruption of arterial perivascular drainage of amyloid-β from the brains of mice expressing the human APOE ε4 allele. PLoS One (2012) 1.22
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res Ther (2010) 1.20
Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study. Int J Geriatr Psychiatry (2002) 1.18
Signalling between the hindbrain and paraxial tissues dictates neural crest migration pathways. Development (2002) 1.16
The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. Cancer Prev Res (Phila) (2014) 1.16
Population studies of sporadic cerebral amyloid angiopathy and dementia: a systematic review. BMC Neurol (2009) 1.16
Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors. Curr Med Res Opin (2003) 1.16
Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am J Transl Res (2009) 1.15
Elevated activity and microglial expression of myeloperoxidase in demyelinated cerebral cortex in multiple sclerosis. Brain Pathol (2007) 1.15
The role of the immune system in clearance of Abeta from the brain. Brain Pathol (2008) 1.14
Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial). Am J Geriatr Psychiatry (2009) 1.14
Distribution and expression of picalm in Alzheimer disease. J Neuropathol Exp Neurol (2010) 1.13
Predicting cognitive decline in Alzheimer's disease: an integrated analysis. Alzheimers Dement (2010) 1.11
Consistency of neuropsychiatric syndromes across dementias: results from the European Alzheimer Disease Consortium. Part II. Dement Geriatr Cogn Disord (2007) 1.10
Grouping for behavioral and psychological symptoms in dementia: clinical and biological aspects. Consensus paper of the European Alzheimer disease consortium. Eur Psychiatry (2005) 1.09
Primary care factors associated with cervical screening coverage in England. J Public Health (Oxf) (2012) 1.09
Epilepsy surgery for refractory epilepsy due to encephalocele: a case report and review of the literature. Epileptic Disord (2010) 1.09
Modelling long-term effects of IGRs on honey bee colonies. Pest Manag Sci (2007) 1.07
Does anxiety affect risk of dementia? Findings from the Caerphilly Prospective Study. Psychosom Med (2009) 1.06
The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol (2006) 1.06
The pathogenesis of neonatal post-hemorrhagic hydrocephalus. Brain Pathol (2004) 1.06
Genetic variants of ABCA1 modify Alzheimer disease risk and quantitative traits related to beta-amyloid metabolism. Hum Mutat (2004) 1.06
Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease. Alzheimers Dement (2010) 1.05
Neprilysin and insulin-degrading enzyme levels are increased in Alzheimer disease in relation to disease severity. J Neuropathol Exp Neurol (2009) 1.05
Endothelin-converting enzyme-2 is increased in Alzheimer's disease and up-regulated by Abeta. Am J Pathol (2009) 1.05
Measurement of pre- and post-synaptic proteins in cerebral cortex: effects of post-mortem delay. J Neurosci Methods (2004) 1.04
Recent advances in the genetics of the ALS-FTLD complex. Curr Neurol Neurosci Rep (2012) 1.04
Application of geographic modeling techniques to quantify spatial access to health services before and after an acute cardiac event: the Cardiac Accessibility and Remoteness Index for Australia (ARIA) project. Circulation (2012) 1.04
Can people with mild to moderate dementia provide reliable answers about their quality of life? Age Ageing (2007) 1.04
Keep music live: music and the alleviation of apathy in dementia subjects. Int Psychogeriatr (2006) 1.03
Changes with age in the activities of beta-secretase and the Abeta-degrading enzymes neprilysin, insulin-degrading enzyme and angiotensin-converting enzyme. Brain Pathol (2010) 1.03
Inflammatory components in human Alzheimer's disease and after active amyloid-β42 immunization. Brain (2013) 1.03